Stay updated with the latest emcure-pharmaceuticals news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on emcure-pharmaceuticals topics.
Bangalore : Emcure Pharmaceuticals Ltd., (BSE: 544210, NSE: EMCURE) has announced the price revision of its weight management drug Poviztra® (semaglutide injection) across India. The reduced price would be starting at Rs. 3,999/- per month (4 weekly doses). The innovator Semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. It comes in a state-of-the-art pen device that provides the convenience of simple admini ...Read More >
Mumbai: Emcure Pharmaceuticals has reduced the price of its weight management drug Poviztra (semaglutide injection) across India by an average of 47% across dosages in a bid to widen patient access. The starting dose price is cut by 55% to Rs 3,999 per month (four weekly doses). The innovator semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg with the highest dose priced at Rs 8,999 for a month's supply. Em ...Read More >
New Delhi, Apr 2 (PTI) Emcure Pharmaceuticals on Thursday announced a reduction in the price of its weight management drug, Poviztra, a semaglutide injection, by up to 55 per cent to expand patient access. The starting dose of Poviztra (0.25 mg) will now be available at Rs 3,999 per month (inclusive of taxes), a reduction of 55 per cent from the previous price of Rs 8,790, with the price reduction effective from April 3, 2026. Across all doses, the price of Poviztra has been reduced by an aver ...Read More >
New Delhi, Sep 26 (PTI) US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 is unlikely to have an immediate impact on Indian exports, as it will affect only patented and branded products, not generic medicines, pharma industry players said on Friday. Indian Pharmaceutical Alliance (IPA), which represents 23 leading Indian pharmaceutical firms, including Dr Reddy's Laboratories, Sun Pharma, Lupin and Zydus Lifesciences, noted that Trump' ...Read More >
Bengaluru : Emcure Pharmaceuticals Ltd. ("Emcure") and Sanofi India Limited ("SIL") today entered into an exclusive distribution and promotion agreement for SIL's oral anti-diabetic (OAD) products in India, effective immediately. Emcure will exclusively distribute and promote the Company's OAD range of products that include well-established brands like Amaryl® and Cetapin®. While SIL will continue to own and manufacture these brands across Sanofi's plants in India and internationally, Emcure w ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.